Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more
Avidity Biosciences, Inc (RNAM) - Net Assets
Latest net assets as of December 2025: $1.69 Billion USD
Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) has net assets worth $1.69 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.96 Billion) and total liabilities ($269.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.69 Billion |
| % of Total Assets | 86.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | 342.7% |
| 10-Year Change | N/A |
| Growth Volatility | 68.87 |
Avidity Biosciences, Inc - Net Assets Trend (2018–2025)
This chart illustrates how Avidity Biosciences, Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual net assets of Avidity Biosciences, Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.69 Billion | +18.50% |
| 2024-12-31 | $1.42 Billion | +184.56% |
| 2023-12-31 | $500.76 Million | -13.37% |
| 2022-12-31 | $578.08 Million | +51.55% |
| 2021-12-31 | $381.43 Million | +24.56% |
| 2020-12-31 | $306.22 Million | +568.54% |
| 2019-12-31 | $-65.36 Million | -58.91% |
| 2018-12-31 | $-41.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avidity Biosciences, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 153614200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00K | 0.00% |
| Other Comprehensive Income | $2.56 Million | 0.15% |
| Other Components | $3.26 Billion | 193.28% |
| Total Equity | $1.69 Billion | 100.00% |
Avidity Biosciences, Inc Competitors by Market Cap
The table below lists competitors of Avidity Biosciences, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aspeed Technology
TWO:5274
|
$9.45 Billion |
|
Innovent Biologics Inc
PINK:IVBXF
|
$9.46 Billion |
|
GEA GROUP
XETRA:G1A
|
$9.48 Billion |
|
Fresenius Medical Care AG & Co. KGaA
PINK:FMCQF
|
$9.48 Billion |
|
Siemens Healthineers AG
PINK:SEMHF
|
$9.43 Billion |
|
Equitable Holdings Inc
F:AXJ
|
$9.41 Billion |
|
Agree Realty Corporation
NYSE:ADC
|
$9.41 Billion |
|
DocuSign Inc
NASDAQ:DOCU
|
$9.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avidity Biosciences, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,424,959,000 to 1,688,600,000, a change of 263,641,000 (18.5%).
- Net loss of 684,631,000 reduced equity.
- New share issuances of 836,882,000 increased equity.
- Other comprehensive income decreased equity by 340,000.
- Other factors increased equity by 111,730,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-684.63 Million | -40.54% |
| Share Issuances | $836.88 Million | +49.56% |
| Other Comprehensive Income | $-340.00K | -0.02% |
| Other Changes | $111.73 Million | +6.62% |
| Total Change | $- | 18.50% |
Book Value vs Market Value Analysis
This analysis compares Avidity Biosciences, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.82x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.10 | $71.34 | x |
| 2019-12-31 | $-1.74 | $71.34 | x |
| 2020-12-31 | $14.14 | $71.34 | x |
| 2021-12-31 | $9.21 | $71.34 | x |
| 2022-12-31 | $11.08 | $71.34 | x |
| 2023-12-31 | $6.86 | $71.34 | x |
| 2024-12-31 | $12.77 | $71.34 | x |
| 2025-12-31 | $12.26 | $71.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avidity Biosciences, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3650.39%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.16x
- Recent ROE (-40.54%) is below the historical average (-22.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -2959.37% | 0.10x | 0.00x | $-7.10 Million |
| 2019 | 0.00% | -1066.58% | 0.02x | 0.00x | $-18.20 Million |
| 2020 | -14.48% | -653.53% | 0.02x | 1.09x | $-74.98 Million |
| 2021 | -30.94% | -1265.38% | 0.02x | 1.12x | $-156.15 Million |
| 2022 | -30.10% | -1886.33% | 0.01x | 1.11x | $-231.80 Million |
| 2023 | -42.38% | -2219.87% | 0.02x | 1.26x | $-262.30 Million |
| 2024 | -22.62% | -2957.71% | 0.01x | 1.10x | $-464.80 Million |
| 2025 | -40.54% | -3650.39% | 0.01x | 1.16x | $-853.49 Million |
Industry Comparison
This section compares Avidity Biosciences, Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avidity Biosciences, Inc (RNAM) | $1.69 Billion | 0.00% | 0.16x | $9.43 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |